Fentanyl
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Fentanyl: Nephrogenic syndrome of inappropriate antidiuresis
One-Sentence Summary
Fentanyl is a potent mu-opioid analgesic, and the sublingual tablet is registered in Australia (ARTG entry for Abstral). The TxGNN model’s top prediction is nephrogenic syndrome of inappropriate antidiuresis (NSIAD), but there are 0 clinical trials and 0 publications supporting it. The evidence is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 0.9946 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Fentanyl is known to be a mu-opioid receptor agonist used for analgesia.
For the top prediction, the mechanistic link is weak. NSIAD is caused by gain-of-function variants in the vasopressin V2 receptor (AVPR2) pathway. Fentanyl has no known direct action on this receptor. Opioids can modulate antidiuretic hormone release, but that would not correct a receptor-level defect. The score (0.9946) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other predictions fare similarly:
- Tourette syndrome, trichotillomania, manic bipolar disorder, migraine with brainstem aura: There is no supportive treatment evidence. Opioid-system involvement has been hypothesised for tic and compulsive disorders, but the agents studied there are antagonists such as naltrexone, not agonists. Opioids are generally discouraged in migraine because of medication-overuse headache.
- This is co-occurrence, not treatment.
- However, long-term opioid use in musculoskeletal pain carries risks of tolerance, dependence and hyperalgesia.
Clinical Trial Evidence
No clinical trials are registered for the top-ranked indication (NSIAD). Currently no related clinical trials registered.
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00343733 | Phase 3 | Completed | 120 | 12-week open-label study with three within-patient double-blind, placebo-controlled periods of OraVescent fentanyl citrate for breakthrough pain in opioid-tolerant patients with noncancer chronic pain. The population is chronic noncancer pain, not confirmed as myofascial pain, so relevance is unverified. |
No ANZCTR identifiers were available in the data compiled for this report.
Literature Evidence
No literature is available for NSIAD. Currently no related literature available.
For reference, the most relevant publications linked to lower-ranked predictions are:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23809446 | 2013 | RCT | Arthroscopy | Postoperative fentanyl patch versus subacromial bupivacaine infusion after arthroscopic shoulder surgery (tendinitis prediction; addresses surgical pain, not tendinitis) |
| 21419546 | 2011 | Review | J Oral Maxillofac Surg | Long-term opioid use in temporomandibular joint dysfunction can be neither supported nor refuted; evidence supports opioids in other chronic noncancer pain states (myofascial pain prediction) |
| 12369265 | 2002 | Mechanistic pilot study | Prog Neuropsychopharmacol Biol Psychiatry | Fentanyl-induced prolactin response used as an opiate receptor sensitivity test in stereotypic movement disorder and trichotillomania; a diagnostic probe, not a treatment study |
| 15102255 | 2001 | Case report | Pain Medicine | Limited absorption of transdermal fentanyl in two patients with systemic sclerosis, one treated for deltoid tendinitis pain |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10600X | Abstral | Tablet (sublingual) 200 micrograms (as citrate) | Not stated in the data compiled for this report |
Safety Considerations
Safety information from the TGA-approved Product Information was not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI).
- Drug Interactions: 100 interactions were identified. Examples rated Major: alvimopan, aprepitant, bupropion, clarithromycin, clotrimazole, dexamethasone, dexfenfluramine, dolasetron, fenfluramine, granisetron and lorcaserin. Examples rated Moderate: atropine, cimetidine, clidinium, dicyclomine, dronabinol, eluxadoline, glycopyrronium and hyoscyamine.
- Knowledge-graph contraindication signals (from a knowledge graph, not label text): hypertension, orthostatic and other hypotensive disorders, long QT syndrome and torsades de pointes, liver failure and liver disease, kidney disease, chronic obstructive pulmonary disease, asthma, pancreatitis, gallbladder disease, inflammatory bowel disease, benign prostatic hyperplasia, anxiety and related disorders, and substance abuse/dependence.
- General class concerns noted in the evidence: abuse liability, respiratory depression, tolerance and dependence, and medication-overuse headache.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (NSIAD) has no clinical or published support and no plausible mechanistic link, because the disease is driven by a receptor-level defect that fentanyl does not address. Overall evidence is L5, and the safety profile of a potent opioid calls for caution.
To proceed, the following is needed:
- Mechanism of action data for fentanyl
- The approved indication text and Product Information (warnings and contraindications) for the Abstral ARTG entry
- Route compatibility assessment (not yet completed)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.